Go to the list of all blogs
published in Blogs
Jul 16, 2026
VXX: Examining the -29% Decline in the iPath Series B S&P 500 VIX Short-Term Futures ETN

VXX: Examining the -29% Decline in the iPath Series B S&P 500 VIX Short-Term Futures ETN

Key Takeaways

  • VXX is an exchange-traded note (ETN) issued by Barclays that tracks the S&P 500 VIX Short-Term Futures Index, providing exposure to a daily rolling blend of first- and second-month VIX futures contracts.
  • The product is structurally designed as a short-term tactical instrument for hedging or speculation, and is not suitable for buy-and-hold strategies due to persistent contango decay that erodes value over time.
  • The Cboe Volatility Index (VIX) has remained subdued near 16–17, yet individual stock volatility as measured by VIXEQ has surged above 46, creating the widest gap between index-level and stock-level implied volatility in over two decades.
  • VXX carries an expense ratio of 0.89% and, as an ETN, embeds the credit risk of Barclays Bank PLC, distinguishing it from exchange-traded funds structured as bankruptcy-remote vehicles.
  • With approximately $400–500 million in assets under management (AUM), VXX remains one of the most liquid volatility-linked exchange-traded products, averaging over 8 million shares traded daily.

Understanding the VXX ETN Structure

VXX is an exchange-traded note that seeks to deliver the return of the S&P 500 VIX Short-Term Futures Index Total Return. Unlike an exchange-traded fund (ETF) that owns underlying assets, an ETN is an unsecured debt obligation of its issuer—in this case, Barclays Bank PLC. The note provides exposure to a daily rolling long position in the first- and second-month VIX futures contracts, effectively reflecting market participants' expectations of near-term S&P 500 implied volatility.

The product's single-asset portfolio holds VIX futures contracts exclusively, with the weighting between the front-month and second-month contracts adjusted daily to maintain a constant 30-day weighted average maturity. This construction means VXX does not track the spot VIX index directly—an important distinction, since VIX futures typically trade at a premium to spot VIX in a condition known as contango. The expense ratio is 0.89%, and the note pays no dividends. VXX was launched in its current Series B form in January 2018 and has undergone multiple reverse splits over its history, most recently a 1-for-4 split in July 2024, reflecting the structural erosion inherent in its design.

The Current Volatility Paradox

The volatility product landscape in mid-2026 is defined by a striking paradox. The Cboe Volatility Index, widely regarded as Wall Street's fear gauge, has hovered near 16–17, a level historically associated with market complacency. Yet beneath this placid surface, the S&P 500 Component Stock Volatility Index (VIXEQ) has climbed to approximately 46–50, representing a year-to-date increase of roughly 46%. The divergence between VIX and VIXEQ has widened to levels not seen since the dot-com era, prompting Bank of America's equity derivatives team to warn that "market shock risk is real."

Several factors contribute to this environment. Sector rotation from technology into defensive areas such as healthcare, consumer staples, and utilities has accelerated, while semiconductor stocks have exhibited extreme individual volatility. The three-month implied correlation index has fallen below 10, its lowest level in two decades, meaning S&P 500 constituents are moving increasingly independently of one another. Meanwhile, the VIX futures term structure remains in contango, with longer-dated contracts priced above near-term contracts—a configuration that imposes a persistent roll cost on long volatility products like VXX. Goldman Sachs has noted that implied correlation near 20-year lows leaves markets vulnerable to sudden correlation spikes, which could rapidly reprice volatility expectations.

Recent Performance Trends

VXX has experienced a steady decline over recent months, consistent with the contango-driven erosion that defines the product during periods of relative equity market calm. From late April through mid-July 2026, the note declined approximately 29%, reflecting both the roll cost embedded in daily futures repositioning and the broader compression in index-level implied volatility. Over the most recent 30-day period, VXX's price movement remained negative but moderated to a single-digit decline, as the VIX found a floor near the 16 level and short-covering in volatility-linked products occasionally provided temporary support.

Year-to-date, VXX has posted a negative total return exceeding 15%, while its trailing one-year return stands near negative 54% and its annualized five-year return is approximately negative 45%. These figures underscore the mathematical reality of holding a product that must continually sell cheaper near-month futures and purchase more expensive next-month contracts when the VIX futures curve slopes upward—which it does roughly 80% of the time. Institutional positioning data indicates that the number of funds and institutions reporting VXX positions has fluctuated between approximately 68 and 93 entities in recent quarters, with average portfolio weights remaining modest at roughly 0.15% to 0.21% of reported portfolios, consistent with its role as a tactical overlay rather than a core allocation.

It is worth emphasizing that VXX's performance trajectory is not primarily driven by traditional sector or stock-level fundamentals. As a pure volatility instrument, its price responds to changes in implied volatility expectations, the slope of the VIX futures curve, and episodic market stress events. The recent narrowing of VXX's decline rate corresponds with the VIX stabilizing after a period of moderate compression, rather than any improvement in the product's structural characteristics.

Using AI for Market Opportunity Identification

In my research process, I also checked this using Tickeron's AI Screener to see how volatility-linked products compare to others in the space. For investors seeking to identify volatility opportunities, trending securities, or breakout candidates across thousands of equities and ETFs, Tickeron's AI Screener provides an AI-powered discovery platform that scans markets using technical indicators, fundamental metrics, volatility measures, price patterns, and AI-generated trading signals. The screener helps users filter securities by industry, market capitalization, performance characteristics, and customizable criteria, enabling faster and more efficient opportunity identification than manual screening methods. For traders monitoring volatility-linked products, the platform's real-time scanning capabilities can surface actionable signals across diverse market environments. Explore the AI Screener to discover new trading ideas and stay ahead of evolving market conditions.

Forward Outlook and Monitoring Points

Looking ahead, several structural factors are likely to influence VXX and the broader volatility product ecosystem. The trajectory of monetary policy remains central: if the Federal Reserve holds rates steady or signals future cuts in response to softening economic data, equity markets may experience reduced index-level turbulence, further compressing the VIX and intensifying contango-related decay. Conversely, any upside inflation surprise or hawkish repricing could trigger equity dislocations that benefit long volatility positions, at least temporarily.

The ongoing divergence between index-level and single-stock volatility warrants close attention. Historically, extreme gaps between VIX and VIXEQ have preceded episodes of rapid volatility convergence—most recently during the August 2024 yen carry trade unwind, when the VIX surged above 65. A similar convergence in 2026 could generate sharp but potentially short-lived spikes in VXX, though the product's daily roll mechanism means gains may be partially offset if the futures curve normalizes quickly. Geopolitical developments, including Middle East tensions and their impact on energy markets, represent additional catalysts that could disrupt the low-VIX regime.

Regulatory and structural considerations also matter. The ETN wrapper remains under periodic scrutiny from regulators concerned about the suitability of complex exchange-traded products for retail investors. Additionally, competition from alternative volatility products, including leveraged and inverse VIX ETFs, continues to fragment the volatility ETP market. Investors evaluating VXX should weigh these structural headwinds against the product's liquidity and accessibility as a tactical hedging instrument, always recognizing that its design mandates short holding periods and carries the distinct credit risk of its issuer.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VXX

Momentum Indicator for VXX turns negative, indicating new downward trend

VXX saw its Momentum Indicator move below the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In of the 77 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VXX turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VXX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VXX broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VXX entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VXX advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Industry description

The investment seeks return linked to the performance of the S&P 500® VIX Short-Term Futures Index TR. The ETN offers exposure to futures contracts of specified maturities on the VIX index and not direct exposure to the VIX index or its spot level. The index is designed to provide investors with exposure to one or more maturities of futures contracts on the CBOE Volatility Index®.
View a ticker or compare two or three
VXX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Miscellaneous
Address
1 Churchill PlaceCanary WharfLondon
Phone
011-44-20-7116-1000
Web
www.barclaysinvestments.co.uk
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.